Paper Details

  1. Home
  2. Paper Details

Prediction of clinical benefits of ritonavir-boosted TMC114 from treatment effects on CD4 counts and HIV RNA.

Author: HillA, MontanerJ, SmithC

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Two independent methods, based on CD4 counts and HIV RNA levels, predicted a 47-55% reduction in progression to AIDS/death in patients receiving TMC114/ritonavir compared to a control protease inhibitor. This pooled analysis of two randomized trials involving patients with HIV infection suggests that these methods could be used to estimate the clinical benefits of other antiretrovirals.
Paper Details　
Original Abstract of the Article :
OBJECTIVE: The aim of the study was to predict reductions in progression to AIDS/death associated with the treatment benefit of antiretrovirals on CD4 counts and HIV RNA in the era of highly active antiretroviral therapy (HAART). DESIGN: The study design was a pooled analysis of two trials (POWER 1...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/j.1468-1293.2007.00466.x

データ提供：米国国立医学図書館（NLM）

Predicting Clinical Benefits of Ritonavir-Boosted TMC114: A Pooled Analysis of Two Trials

The relentless battle against HIV/AIDS has yielded significant progress, with the advent of highly active antiretroviral therapy (HAART) revolutionizing treatment strategies. This study explores the potential of a new antiretroviral combination, ritonavir-boosted TMC114 (TMC114/r), to improve clinical outcomes in HIV-infected patients. The researchers conducted a pooled analysis of two trials, POWER 1 and POWER 2, to evaluate the treatment's impact on CD4 counts, HIV RNA levels, and clinical progression to AIDS or death.

A Powerful Combination: TMC114/r Demonstrates Significant Benefits

The study revealed a significant treatment benefit of TMC114/r compared to a control protease inhibitor. TMC114/r significantly increased CD4 counts and reduced HIV RNA levels, leading to a substantial reduction in the hazard of clinical progression to AIDS or death. The researchers used both CD4 categorization and regression methods to predict clinical benefits, both suggesting a significant reduction in progression risk for TMC114/r treatment. These findings highlight the potential of TMC114/r as a powerful addition to the armamentarium against HIV/AIDS.

Navigating the Desert of HIV Treatment: A Quest for Improved Outcomes

The study's findings provide valuable insights into the potential of TMC114/r as an effective antiretroviral therapy. This research underscores the importance of continued research and development of new therapies to optimize clinical outcomes in HIV-infected individuals. The researchers' use of multiple prediction methods to estimate clinical benefits provides a robust foundation for future research endeavors, paving the way for even more effective and personalized treatment strategies for those living with HIV/AIDS.

Dr.Camel's Conclusion

This study demonstrates the significant clinical benefits of ritonavir-boosted TMC114 (TMC114/r) in treating HIV-infected patients. TMC114/r effectively increased CD4 counts, reduced HIV RNA levels, and significantly reduced the risk of clinical progression to AIDS or death. This research underscores the importance of ongoing efforts to develop new and improved antiretroviral therapies for HIV/AIDS.

Date :
  1. Date Completed 2007-12-20
  2. Date Revised 2015-11-19
Further Info :

Pubmed ID

17461851

DOI: Digital Object Identifier

10.1111/j.1468-1293.2007.00466.x

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.